Home
RGNX
RGNX News

Latest REGENXBIO Inc. (RGNX) News on July 27, 2024

REGENXBIO to Host Conference Call on August 1 to Discuss Second Quarter 2024 Financial Results and Recent Operational Highlights

PR Newswire

2 days ago

REGENXBIO to Host Conference Call on August 1 to Discuss Second Quarter 2024 Financial Results and Recent Operational Highlights

Argus Research

3 days ago

RGNX: What does Argus have to say about RGNX?

Argus Research

10 days ago

RGNX: Raising target price to $14.00

Regenxbio (RGNX) Surges 18.3%: Is This an Indication of Further Gains?

Zacks

14 days ago

Regenxbio (RGNX) Surges 18.3%: Is This an Indication of Further Gains?

Argus Research

17 days ago

RGNX: What does Argus have to say about RGNX?

Here's Why Sarepta (SRPT) Stock Price Surged 57% YTD

Zacks

18 days ago

Here's Why Sarepta (SRPT) Stock Price Surged 57% YTD

Argus Research

24 days ago

RGNX: Lowering target price to $11.00

Why Did Analysts Maintain a Bullish Stance on REGENXBIO Inc. (RGNX) Despite Decline In Its Revenue Growth?

Insider Monkey

a month ago

Why Did Analysts Maintain a Bullish Stance on REGENXBIO Inc. (RGNX) Despite Decline In Its Revenue Growth?

Regenxbio (RGNX) Soars 6.4%: Is Further Upside Left in the Stock?

Zacks

a month ago

Regenxbio (RGNX) Soars 6.4%: Is Further Upside Left in the Stock?

MT Newswires

a month ago

Regenxbio Enrolling New Group for Phase 1/2 Duchenne Muscular Dystrophy Trial

REGENXBIO Announces Expansion of AFFINITY DUCHENNE® Trial to Include a New Cohort of Younger Patients

PR Newswire

a month ago

REGENXBIO Announces Expansion of AFFINITY DUCHENNE® Trial to Include a New Cohort of Younger Patients

Sarepta Catapults 30% After Hitting A 'Grand Slam' Approval In Muscular Dystrophy

Investor's Business Daily

a month ago

Sarepta Catapults 30% After Hitting A 'Grand Slam' Approval In Muscular Dystrophy

FDA Expands Sarepta's (SRPT) DMD Gene Therapy Label

Zacks

a month ago

FDA Expands Sarepta's (SRPT) DMD Gene Therapy Label

MT Newswires

a month ago

Regenxbio Reports 'Successful' Meeting With FDA For RGX-121

REGENXBIO Announces Successful Pre-BLA Meeting with FDA to Support Accelerated Approval Pathway for RGX-121 for the Treatment of MPS II

PR Newswire

a month ago

REGENXBIO Announces Successful Pre-BLA Meeting with FDA to Support Accelerated Approval Pathway for RGX-121 for the Treatment of MPS II

Sanofi taps Belharra for immune drug research; AstraZeneca’s new cancer drug falls short

BioPharma Dive

a month ago

Sanofi taps Belharra for immune drug research; AstraZeneca’s new cancer drug falls short

Urogen Pharma (URGN) Surges 9.7%: Is This an Indication of Further Gains?

Zacks

a month ago

Urogen Pharma (URGN) Surges 9.7%: Is This an Indication of Further Gains?

MT Newswires

a month ago

Regenxbio Names Curran Simpson President, CEO

Regenxbio CEO to step down after 15 years

BioPharma Dive

a month ago

Regenxbio CEO to step down after 15 years

REGENXBIO Announces Leadership Transition

PR Newswire

a month ago

REGENXBIO Announces Leadership Transition

REGENXBIO to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

PR Newswire

2 months ago

REGENXBIO to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

It Looks Like REGENXBIO Inc.'s (NASDAQ:RGNX) CEO May Expect Their Salary To Be Put Under The Microscope

Simply Wall St.

2 months ago

It Looks Like REGENXBIO Inc.'s (NASDAQ:RGNX) CEO May Expect Their Salary To Be Put Under The Microscope

MT Newswires

2 months ago

HC Wainwright Adjusts Price Target on REGENXBIO to $38 From $36, Maintains Buy Rating

Analysts Have Lowered Expectations For REGENXBIO Inc. (NASDAQ:RGNX) After Its Latest Results

Simply Wall St.

3 months ago

Analysts Have Lowered Expectations For REGENXBIO Inc. (NASDAQ:RGNX) After Its Latest Results

Regenxbio Inc (RGNX) Q1 2024 Earnings: Misses Analyst Revenue and EPS Forecasts

GuruFocus.com

3 months ago

Regenxbio Inc (RGNX) Q1 2024 Earnings: Misses Analyst Revenue and EPS Forecasts

REGENXBIO to Participate in Upcoming Investor Conferences

PR Newswire

3 months ago

REGENXBIO to Participate in Upcoming Investor Conferences

REGENXBIO Inc. (NASDAQ:RGNX) Q1 2024 Earnings Call Transcript

Insider Monkey

3 months ago

REGENXBIO Inc. (NASDAQ:RGNX) Q1 2024 Earnings Call Transcript

MT Newswires

3 months ago

UBS Adjusts Price Target on REGENXBIO to $39 From $43, Maintains Buy Rating

Thomson Reuters StreetEvents

3 months ago

Q1 2024 Regenxbio Inc Earnings Call

GuruFocus.com

3 months ago

Regenxbio Inc (RGNX) Q1 2024 Earnings Call Transcript Highlights: Strategic Progress and Robust ...

Regenxbio (RGNX) Reports Q1 Loss, Lags Revenue Estimates

Zacks

3 months ago

Regenxbio (RGNX) Reports Q1 Loss, Lags Revenue Estimates

Associated Press Finance

3 months ago

Regenxbio: Q1 Earnings Snapshot

REGENXBIO Reports First Quarter 2024 Financial Results and Recent Operational Highlights

PR Newswire

3 months ago

REGENXBIO Reports First Quarter 2024 Financial Results and Recent Operational Highlights

REGENXBIO to Host Conference Call on May 8 to Discuss First Quarter 2024 Financial Results and Recent Operational Highlights

PR Newswire

3 months ago

REGENXBIO to Host Conference Call on May 8 to Discuss First Quarter 2024 Financial Results and Recent Operational Highlights

REGENXBIO to Participate in Chardan's 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit

PR Newswire

3 months ago

REGENXBIO to Participate in Chardan's 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit

Argus Research

3 months ago

RGNX: Lowering target price to $17.00

REGENXBIO Inc.'s (NASDAQ:RGNX) recent 7.9% pullback adds to one-year year losses, institutional owners may take drastic measures

Simply Wall St.

3 months ago

REGENXBIO Inc.'s (NASDAQ:RGNX) recent 7.9% pullback adds to one-year year losses, institutional owners may take drastic measures

REGENXBIO Sees Positive Results For Macular Degeneration Therapy

Exec Edge

4 months ago

REGENXBIO Sees Positive Results For Macular Degeneration Therapy

REGENXBIO Announces Lancet Publication of Phase I/IIa Study Evaluating ABBV-RGX-314 as a One-Time Gene Therapy for Wet AMD

PR Newswire

4 months ago

REGENXBIO Announces Lancet Publication of Phase I/IIa Study Evaluating ABBV-RGX-314 as a One-Time Gene Therapy for Wet AMD

REGENXBIO to Participate in Cantor Fitzgerald's Virtual DMD and Other Dystrophy Days

PR Newswire

4 months ago

REGENXBIO to Participate in Cantor Fitzgerald's Virtual DMD and Other Dystrophy Days

Regenxbio Inc (RGNX) President and CEO Kenneth Mills Sells 15,000 Shares

GuruFocus.com

4 months ago

Regenxbio Inc (RGNX) President and CEO Kenneth Mills Sells 15,000 Shares

Does This 1 New Threat Make Sarepta Therapeutics Stock Worth Selling?

Motley Fool

4 months ago

Does This 1 New Threat Make Sarepta Therapeutics Stock Worth Selling?

REGENXBIO to Participate in Upcoming Investor Conferences

PR Newswire

5 months ago

REGENXBIO to Participate in Upcoming Investor Conferences

Regenxbio Inc (RGNX) Chief Medical Officer Steve Pakola Sells 12,878 Shares

GuruFocus.com

5 months ago

Regenxbio Inc (RGNX) Chief Medical Officer Steve Pakola Sells 12,878 Shares

Bearish: Analysts Just Cut Their REGENXBIO Inc. (NASDAQ:RGNX) Revenue and EPS estimates

Simply Wall St.

5 months ago

Bearish: Analysts Just Cut Their REGENXBIO Inc. (NASDAQ:RGNX) Revenue and EPS estimates

REGENXBIO Announces Pricing of Upsized Public Offering of Common Stock and Pre-funded Warrants

PR Newswire

5 months ago

REGENXBIO Announces Pricing of Upsized Public Offering of Common Stock and Pre-funded Warrants

REGENXBIO Announces Proposed Public Offering of Common Stock

PR Newswire

5 months ago

REGENXBIO Announces Proposed Public Offering of Common Stock

REGENXBIO (RGNX) Soars 15% on Interim Data From DMD Study

Zacks

5 months ago

REGENXBIO (RGNX) Soars 15% on Interim Data From DMD Study

Regenxbio data suggest ‘niche’ in Duchenne gene therapy

BioPharma Dive

5 months ago

Regenxbio data suggest ‘niche’ in Duchenne gene therapy

REGENXBIO ANNOUNCES NEW POSITIVE INITIAL EFFICACY DATA FROM AFFINITY DUCHENNE® TRIAL

PR Newswire

5 months ago

REGENXBIO ANNOUNCES NEW POSITIVE INITIAL EFFICACY DATA FROM AFFINITY DUCHENNE® TRIAL

REGENXBIO to Host Webcast Event to Discuss New Interim Clinical Data from the Phase I/II AFFINITY DUCHENNE® Trial

PR Newswire

5 months ago

REGENXBIO to Host Webcast Event to Discuss New Interim Clinical Data from the Phase I/II AFFINITY DUCHENNE® Trial

Thomson Reuters StreetEvents

5 months ago

Q4 2023 Regenxbio Inc Earnings Call

REGENXBIO Inc. (NASDAQ:RGNX) Q4 2023 Earnings Call Transcript

Insider Monkey

5 months ago

REGENXBIO Inc. (NASDAQ:RGNX) Q4 2023 Earnings Call Transcript

Regenxbio (RGNX) Reports Q4 Loss, Lags Revenue Estimates

Zacks

5 months ago

Regenxbio (RGNX) Reports Q4 Loss, Lags Revenue Estimates

Regenxbio Inc (RGNX) Reports Full Year 2023 Financial Results and Operational Highlights

GuruFocus.com

5 months ago

Regenxbio Inc (RGNX) Reports Full Year 2023 Financial Results and Operational Highlights

Associated Press Finance

5 months ago

Regenxbio: Q4 Earnings Snapshot

REGENXBIO Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Operational Highlights

PR Newswire

5 months ago

REGENXBIO Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Operational Highlights

REGENXBIO to Host Conference Call on February 27 to Discuss Fourth Quarter and Full Year 2023 Financial Results and Recent Operational Highlights

PR Newswire

5 months ago

REGENXBIO to Host Conference Call on February 27 to Discuss Fourth Quarter and Full Year 2023 Financial Results and Recent Operational Highlights

Regenxbio Inc President and CEO Kenneth Mills Sells 15,000 Shares

GuruFocus.com

5 months ago

Regenxbio Inc President and CEO Kenneth Mills Sells 15,000 Shares

The Zacks Analyst Blog Highlights Gilead Sciences, Bristol Myers, Amgen, Morphysys and REGENXBIO

Zacks

6 months ago

The Zacks Analyst Blog Highlights Gilead Sciences, Bristol Myers, Amgen, Morphysys and REGENXBIO

Biotech Stock Roundup: GILD, AMGN & BMY's Q4 Results, MOR Up on NVS Deal & More

Zacks

6 months ago

Biotech Stock Roundup: GILD, AMGN & BMY's Q4 Results, MOR Up on NVS Deal & More

REGENXBIO's (RGNX) Hunter Syndrome Study Meets Goal, Stock Up

Zacks

6 months ago

REGENXBIO's (RGNX) Hunter Syndrome Study Meets Goal, Stock Up

Strength Seen in Regenxbio (RGNX): Can Its 11.7% Jump Turn into More Strength?

Zacks

6 months ago

Strength Seen in Regenxbio (RGNX): Can Its 11.7% Jump Turn into More Strength?

REGENXBIO Announces Pivotal Trial of RGX-121 for the Treatment of MPS II Achieves Primary Endpoint

PR Newswire

6 months ago

REGENXBIO Announces Pivotal Trial of RGX-121 for the Treatment of MPS II Achieves Primary Endpoint

REGENXBIO Announces Completion of Enrollment in Cohort 2 and Additional Positive Interim Data in AFFINITY DUCHENNE® Trial

PR Newswire

6 months ago

REGENXBIO Announces Completion of Enrollment in Cohort 2 and Additional Positive Interim Data in AFFINITY DUCHENNE® Trial

Ramaco Announces Hiring of Distinguished West Virginian as New General Counsel; First Quarter 2024 Class B Dividend Declared

PR Newswire

6 months ago

Ramaco Announces Hiring of Distinguished West Virginian as New General Counsel; First Quarter 2024 Class B Dividend Declared

Strength Seen in Silence Therapeutics PLC Sponsored ADR (SLN): Can Its 15.4% Jump Turn into More Strength?

Zacks

6 months ago

Strength Seen in Silence Therapeutics PLC Sponsored ADR (SLN): Can Its 15.4% Jump Turn into More Strength?

Business Wire

6 months ago

B&G Foods Releases Inaugural Corporate Social Responsibility Report

REGENXBIO Announces Presentations at the 20th Annual WORLDSymposium 2024

PR Newswire

6 months ago

REGENXBIO Announces Presentations at the 20th Annual WORLDSymposium 2024

Should You Hold Seneca Foods Corporation (SENEA)?

Insider Monkey

6 months ago

Should You Hold Seneca Foods Corporation (SENEA)?

Byline Bancorp, Inc. (NYSE:BY) Q4 2023 Earnings Call Transcript

Insider Monkey

6 months ago

Byline Bancorp, Inc. (NYSE:BY) Q4 2023 Earnings Call Transcript

Alpha and Omega Semiconductor Announces Closing of DOJ Investigation

Business Wire

6 months ago

Alpha and Omega Semiconductor Announces Closing of DOJ Investigation

MetroCity Bankshares, Inc. (NASDAQ:MCBS) Looks Interesting, And It's About To Pay A Dividend

Simply Wall St.

6 months ago

MetroCity Bankshares, Inc. (NASDAQ:MCBS) Looks Interesting, And It's About To Pay A Dividend

Ethan Allen Reports Fiscal 2024 Second Quarter Results Highlighted by Strong Margins and Robust Balance Sheet; Lower Sales Reflect Post Pandemic Economy

GlobeNewswire

6 months ago

Ethan Allen Reports Fiscal 2024 Second Quarter Results Highlighted by Strong Margins and Robust Balance Sheet; Lower Sales Reflect Post Pandemic Economy

Yext Recognized by Built In as a 2024 Best Place To Work

Business Wire

6 months ago

Yext Recognized by Built In as a 2024 Best Place To Work

The Road Less Traveled: 3 Stocks to Sell as the Electric Vehicle Market Stalls

InvestorPlace

6 months ago

The Road Less Traveled: 3 Stocks to Sell as the Electric Vehicle Market Stalls

Soleno Therapeutics Strengthens Leadership Team with Key Appointments

GlobeNewswire

6 months ago

Soleno Therapeutics Strengthens Leadership Team with Key Appointments

Accolade Welcomes Kindbody to Trusted Partner Ecosystem

PR Newswire

6 months ago

Accolade Welcomes Kindbody to Trusted Partner Ecosystem

The Zacks Analyst Blog Highlights Casey's General Stores, Target, Amazon.com and American Eagle Outfitters

Zacks

6 months ago

The Zacks Analyst Blog Highlights Casey's General Stores, Target, Amazon.com and American Eagle Outfitters

Curious about Peoples Bancorp (PEBO) Q4 Performance? Explore Wall Street Estimates for Key Metrics

Zacks

6 months ago

Curious about Peoples Bancorp (PEBO) Q4 Performance? Explore Wall Street Estimates for Key Metrics

Seeking Clues to Berkshire Hills (BHLB) Q4 Earnings? A Peek Into Wall Street Projections for Key Metrics

Zacks

6 months ago

Seeking Clues to Berkshire Hills (BHLB) Q4 Earnings? A Peek Into Wall Street Projections for Key Metrics

ANI Pharmaceuticals Announces the Launch of Pentoxifylline Extended-Release Tablets, USP

GlobeNewswire

6 months ago

ANI Pharmaceuticals Announces the Launch of Pentoxifylline Extended-Release Tablets, USP

Wix.com (WIX) Exceeds Market Returns: Some Facts to Consider

Zacks

6 months ago

Wix.com (WIX) Exceeds Market Returns: Some Facts to Consider

LanzaTech Global, Inc. (NASDAQ:LNZA): When Will It Breakeven?

Simply Wall St.

6 months ago

LanzaTech Global, Inc. (NASDAQ:LNZA): When Will It Breakeven?

Unpacking Q3 Earnings: BJ's (NASDAQ:BJRI) In The Context Of Other Sit-Down Dining Stocks

StockStory

6 months ago

Unpacking Q3 Earnings: BJ's (NASDAQ:BJRI) In The Context Of Other Sit-Down Dining Stocks

Q3 Earnings Outperformers: Zeta (NYSE:ZETA) And The Rest Of The Advertising Software Stocks

StockStory

6 months ago

Q3 Earnings Outperformers: Zeta (NYSE:ZETA) And The Rest Of The Advertising Software Stocks

Hertz Global Holdings, Inc. (HTZ) Surges 7.5%: Is This an Indication of Further Gains?

Zacks

6 months ago

Hertz Global Holdings, Inc. (HTZ) Surges 7.5%: Is This an Indication of Further Gains?

Regenxbio Inc President and CEO Kenneth Mills Sells 45,000 Shares

GuruFocus.com

6 months ago

Regenxbio Inc President and CEO Kenneth Mills Sells 45,000 Shares

3 Stocks to Buy for Growth and Stability

Zacks

6 months ago

3 Stocks to Buy for Growth and Stability

ACM Research, Inc. (ACMR) is a Great Momentum Stock: Should You Buy?

Zacks

6 months ago

ACM Research, Inc. (ACMR) is a Great Momentum Stock: Should You Buy?

REGENXBIO Announces Positive Interim Data from Phase II AAVIATE® Trial of ABBV-RGX-314 for the Treatment of Wet AMD Using Suprachoroidal Delivery

PR Newswire

6 months ago

REGENXBIO Announces Positive Interim Data from Phase II AAVIATE® Trial of ABBV-RGX-314 for the Treatment of Wet AMD Using Suprachoroidal Delivery

E-ONE Celebrates 50 Years of Fire Industry Leadership and Innovation

Business Wire

6 months ago

E-ONE Celebrates 50 Years of Fire Industry Leadership and Innovation

REGENXBIO Announces Presentation at the Hawaiian Eye and Retina 2024 Meeting

PR Newswire

7 months ago

REGENXBIO Announces Presentation at the Hawaiian Eye and Retina 2024 Meeting

Is Hyster-Yale Materials Handling, Inc. (NYSE:HY) A High Quality Stock To Own?

Simply Wall St.

7 months ago

Is Hyster-Yale Materials Handling, Inc. (NYSE:HY) A High Quality Stock To Own?

Down -25.53% in 4 Weeks, Here's Why You Should You Buy the Dip in Regenxbio (RGNX)

Zacks

7 months ago

Down -25.53% in 4 Weeks, Here's Why You Should You Buy the Dip in Regenxbio (RGNX)

3 Monthly Dividend Stocks for Consistent Passive Income

InvestorPlace

7 months ago

3 Monthly Dividend Stocks for Consistent Passive Income

Volkswagen and Cerence Collaborate to Bring New, Generative AI-Powered Interaction to Drivers

GlobeNewswire

7 months ago

Volkswagen and Cerence Collaborate to Bring New, Generative AI-Powered Interaction to Drivers

U.S. District Court Issues Decision on REGENXBIO and University of Pennsylvania NAV® Technology Patent Infringement Lawsuit

PR Newswire

7 months ago

U.S. District Court Issues Decision on REGENXBIO and University of Pennsylvania NAV® Technology Patent Infringement Lawsuit

Calliditas Therapeutics appoints Maria Törnsén as President North America

PR Newswire

7 months ago

Calliditas Therapeutics appoints Maria Törnsén as President North America

Longboard Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock

Business Wire

7 months ago

Longboard Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock

Share on Social Networks: